Cytrx Corp. (MM) News - CYTR

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE...

CytRx Corporation to Commence Trading on OTCQB Venture Market

CytRx Corporation to Commence Trading on OTCQB Venture Market Company to Continue Trading Under Ticker Symbol...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE...

CytRx Corporation Reports First Quarter 2019 Financial Results

CytRx Corporation Reports First Quarter 2019 Financial Results Out-licensed Assets Aldoxorubicin and...

CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer The...

CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S CytRx...

CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted ...

CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body...

CytRx Corporation Reports 2018 Financial Results

CytRx Corporation Reports 2018 Financial Results LADR™ Assets Well Aligned with Current Oncology Trends...

Annual Report (10-k)

UNITED STATES SECURITIES AND...

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To ...

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could...

CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor

CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to...

CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidate...

CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are...

CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (...

CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washin...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cytrx Corp. (MM) (CYTR)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CYTR News

Statement of Ownership (sc 13g)

Current Report Filing (8-k)

CytRx Corporation to Commence Trading on OTCQB Venture Market

Quarterly Report (10-q)

CytRx Corporation Reports First Quarter 2019 Financial Results

CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted ...

CytRx Corporation Reports 2018 Financial Results

Annual Report (10-k)

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To ...

CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor

CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidate...

CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (...

Current Report Filing (8-k)

CYTR Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cytrx Corp. (MM) (CYTR) News

Cytrx Corp. (MM) (CYTR)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CYTR News

Statement of Ownership (sc 13g)

Current Report Filing (8-k)

CytRx Corporation to Commence Trading on OTCQB Venture Market

Quarterly Report (10-q)

CytRx Corporation Reports First Quarter 2019 Financial Results

CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted ...

CytRx Corporation Reports 2018 Financial Results

Annual Report (10-k)

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To ...

CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor

CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidate...

CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (...

Current Report Filing (8-k)

CYTR Discussion

Your Recent History